QS Investors, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 177 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.62 and the average weighting 0.1%.

Quarter-by-quarter ownership
QS Investors, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2021$2,952,000
+10.8%
65,000
+1.7%
0.04%
+12.9%
Q1 2021$2,664,000
+224.5%
63,900
+232.3%
0.03%
+210.0%
Q4 2020$821,000
+62.3%
19,2320.0%0.01%
+42.9%
Q3 2020$506,000
-77.7%
19,232
-77.2%
0.01%
-78.1%
Q2 2020$2,264,000
+48.4%
84,433
-0.4%
0.03%
+33.3%
Q1 2020$1,526,000
-6.0%
84,806
-5.5%
0.02%
+50.0%
Q4 2019$1,624,000
+15.2%
89,706
-1.3%
0.02%
+6.7%
Q3 2019$1,410,000
-9.7%
90,9020.0%0.02%
-11.8%
Q2 2019$1,562,000
+3.9%
90,902
-2.6%
0.02%
+6.2%
Q1 2019$1,503,000
+10.0%
93,3020.0%0.02%
-11.1%
Q4 2018$1,366,000
-19.4%
93,3020.0%0.02%
+12.5%
Q3 2018$1,695,000
+7.7%
93,3020.0%0.02%0.0%
Q2 2018$1,574,000
-13.9%
93,3020.0%0.02%
-15.8%
Q1 2018$1,828,000
-12.2%
93,302
-9.2%
0.02%
-5.0%
Q4 2017$2,081,000
+23.4%
102,706
+5.8%
0.02%
+42.9%
Q3 2017$1,686,000
+35.5%
97,0610.0%0.01%
+27.3%
Q2 2017$1,244,000
-3.8%
97,061
-2.7%
0.01%0.0%
Q1 2017$1,293,000
+31.3%
99,7460.0%0.01%
+37.5%
Q4 2016$985,000
-18.3%
99,7460.0%0.01%
-11.1%
Q3 2016$1,205,000
+38.8%
99,746
-0.8%
0.01%
+28.6%
Q2 2016$868,000
-8.8%
100,5730.0%0.01%
-22.2%
Q1 2016$952,000
-57.3%
100,573
-21.7%
0.01%
-59.1%
Q4 2015$2,227,000
+57.9%
128,491
+22.4%
0.02%
+46.7%
Q3 2015$1,410,000
-60.2%
104,979
-33.1%
0.02%
-65.9%
Q2 2015$3,542,000
+136.1%
156,879
+49.4%
0.04%
+158.8%
Q1 2015$1,500,000
+47.9%
104,9790.0%0.02%
+41.7%
Q4 2014$1,014,000104,9790.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2016
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders